(ORTX) – Press Releases
-
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
-
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
-
FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy
-
CANNARAY LIMITED ANNOUNCES INTERNATIONAL MERGER WITH AQUALITAS INC.
-
ORI Capital Raises $260 Million for Second Life Sciences Fund
-
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
-
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
-
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
-
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
-
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
-
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
-
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
-
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
-
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
-
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
-
Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm
-
SCORE - Mentors to America's Small Businesses - Announces New Board Members
-
Kyowa Kirin to Acquire Orchard Therapeutics
-
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
-
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
-
FONDAZIONE TELETHON AND ORCHARD THERAPEUTICS COMPLETE TRANSFER OF MARKETING AUTHORIZATION OF STRIMVELIS FOR ADA-SCID IN EUROPE
-
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
-
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
-
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
-
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
-
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
-
Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
-
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
-
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
-
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. F
-
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
-
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
-
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
-
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
-
Orchard Therapeutics Completes ADS Ratio Change
-
Orchard Therapeutics Completes ADS Ratio Change
-
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
-
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
-
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
-
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
-
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
-
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
-
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
-
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
-
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
-
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
-
Orchard Therapeutics Announces Proposed ADS Ratio Change
-
Orchard Therapeutics Announces Proposed ADS Ratio Change
-
Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
-
Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
Back to ORTX Stock Lookup
